In the realm of rare diseases, collaboration among stakeholders—academia, patientorganisations, and industry—is paramount. The synergy created by pooling academic research, patient insights, and industry expertise fosters breakthroughs in understanding and treating these complex conditions.
 
By uniting these forces, we amplify our impact, expedite discoveries, and bring hope to those often overlooked by mainstream healthcare.
 
In this video Professor Marshall Summar elaborates on this topic.

How important is collaboration among different stakeholders for making new treatments for rare diseases available?

In the field of rare disease, one of the central elements is that all parties have to be at the table because there's so much need. It's hard to do things.

We have to have academics, we have to have patients, we have to have industry partners. Without that interaction between academics and industry, we don't get new ideas, we don't get new things that maybe we can take to the patient and see what's going on. 

Without the patients we don't know what the right questions are. We don't know if we're addressing the proper endpoints and we actually try to solve a problem that's relevant to the patients and families.

Without the industry, there's nobody to drive the production or who have the resources to bring new therapies to market.